Macrogen, Inc.

038290· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩11,870+4.12%

2026-08-04

Financials

Valuation Metrics

Macrogen, Inc.'s Market Cap is ₩1287B. At end of 2025 it was ₩1829B. Ranked #1071 of 2,436 in KR market (top 44%), #547 of 1,649 on KOSDAQ (top 33%), #126 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	128.69B KRW	KR#1,071/2,436 Sec#126/234
Revenue	199.60B KRW	KR#1,017/2,436 Sec#59/234
Net Income	2.15B KRW	KR#1,340/2,436 Sec#95/234
Total Assets	368.23B KRW	KR#901/2,436 Sec#55/234
Net Assets	167.37B KRW	KR#1,035/2,436 Sec#74/234
Employees	529	KR#466/2,436 Sec#38/234
Value
P/E	59.94x	KR#1,379/2,436 Sec#90/234
P/B	0.77x	KR#1,233/2,436 Sec#71/234
P/S	0.64x	KR#1,098/2,436 Sec#50/234
EV/EBITDA	64.25x	KR#1,402/2,436 Sec#96/234
FCF Yield	-10.05%	KR—/2,436 Sec—/234
Profitability
ROE	1.28%	KR#1,398/2,436 Sec#97/234
ROA	0.58%	KR#1,398/2,436 Sec#99/234
Op. Margin	1.36%	KR#1,432/2,436 Sec#105/234
Revenue Growth	10.57%	KR#904/2,436 Sec#82/234
Earnings Growth	-133.32%	KR#1,433/2,436 Sec#94/234
Financial Health
Debt Ratio	220.00%	KR#1,838/2,436 Sec#200/234
Total Debt	100.15B KRW	KR#714/2,436 Sec#44/234
FCF	-12.94B KRW	KR#1,788/2,436 Sec#159/234
Cash	54.19B KRW	KR#712/2,436 Sec#42/234
Current Ratio	0.79x	KR#2,043/2,436 Sec#196/234
Net Debt/EBITDA	16.91x	KR#1,391/2,436 Sec#97/234
Dividend
Div. Yield	4.39%	KR#404/2,436 Sec#13/234
Div. Growth	66.67%	KR#171/2,436 Sec#5/234
Performance
1Y Return	-21.55%	KR#1,312/2,436 Sec#109/234
1M Return	-5.79%	KR#1,461/2,436 Sec#145/234
From 52W High	-43.21%	KR#905/2,436 Sec#65/234
1Y MDD	-45.18%	KR#710/2,436 Sec#58/234
Trading
Volume	18,504 shares	KR#1,883/2,436 Sec#188/234
Foreign Own.	4.31%	KR—/2,436 Sec—/234
Per Share
EPS	352 KRW	KR#1,055/2,436 Sec#73/234
BPS	14,017 KRW	KR#701/2,436 Sec#48/234

Company Info

CEO 서정선, 김창훈 (각자 대표이사)

Employees 529

Founded 1997

HQ 서울특별시 강남구, KR

Website www.macrogen.com

동사는 1997년 설립된 정밀의학 생명공학기업으로 2000년 코스닥에 상장되었으며 2023년 유럽법인이 스위스, 일본 법인을 설립함. 유전체 분석, Oligo합성, Microarray 분석, 유전자변형 마우스 제작 등 유전체 서비스 제공하며 CES, NGS 두 분야로 사업 운영하고 있음. 주요 도시 지놈센터 거점을 통해 '$100 DNA 몸 설계도' 제공을 목표로 정밀 맞춤의학 실현에 앞장서고 있음. 마크로젠는 1997년에 설립되었으며 서울특별시 강남구에 본사를 두고 있습니다.